Status:
RECRUITING
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Cancer
Eligibility:
All Genders
20+ years
Brief Summary
Patients with cancer are considered vulnerable to severe acute respiratory syndrome coronavirus 2 infection and have been prioritized in the vaccination process in several countries, including Taiwan....
Detailed Description
Patients with cancer receiving systemic anti-cancer treatments have been generally assumed by many to be at a higher risk from the disease than their counterparts are who are not receiving anticancer ...
Eligibility Criteria
Inclusion Criteria:
- adults >20 years old;
- cancer patients under active anti-cancer therapy, including chemotherapy (n=80), targeted therapy (n=80) and immunotherapy (n=80); and cancer patients have been disease-free for ≥ 6 months (n=80)
- cancer patients who were full vaccinated with any brand of vaccines or cancer patients who were unvaccinated agree to complete full vaccination later.
- patients who agreed with the content of informed consent of the study protocol.
Exclusion Criteria:
- Patients who refused the protocol of N-antibody test and Out-Patient Departments follow-up.
- The investigators suggest to withdraw.
- Patient asked to withdraw from the trial at any timepoints.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2025
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT05384509
Start Date
December 1 2021
End Date
February 28 2025
Last Update
February 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TuCheng Hospital
New Taipei City, Taiwan, 23652